Alterity Therapeutics Ltd - ADR

Alterity Therapeutics Ltd. engages in the research and development into Parkinsonian and other neurodegenerative disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

Earnings data Q2 2023

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from...

Alterity to present at the 7th International Congress of Multiple System Atrophy

Alterity Therapeutics Ltd (ATHE) CEO David Stamler on Q2 2021 Results - Earnings Call Transcript

MELBOURNE, Australia, Dec. 21, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore...

Alterity and UniQuest partner to reverse bacterial resistance to antibiotics

As of 1:46 PM ET, the stock price of Alterity Therapeutics Ltd (NASDAQ: ATHE) (ASX: ATH) is trading up 153.48% at $2.92 (up from the previous close of $1.15). Why is this happening?

Alterity Therapeutics (ATHE) Stock Price Increases Over 150%: Why It Happened

Alterity Therapeutics (ATHE) news for Monday includes approval of a new patent protecting its drugs pushing ATHE stock higher. The post Alterity Therapeutics News: 8 Things for ATHE Stock Investors to Know appeared first on InvestorPlace.

Alterity Therapeutics News: 8 Things for ATHE Stock Investors to Know

Shares of Alterity Therapeutics Ltd (NASDAQ: ATHE) gap-opened Monday's session higher and are sustaining the gains. What Happened: The Australian biopharma said the U.S. Patent and Trademark Office has approved a new composition of matter patent related to its drug development portfolio focused on neurodegenerative diseases.

Why Microcap Biopharma Alterity Therapeutics Is Rallying

The U.S.-listed shares of Alterity Therapeutics Ltd. rocketed 129.6% on massive volume in morning trading Monday, enough to be the biggest gainer among those listed on major U.S. exchanges, after the Australia-based drug maker announced the allowance of a new patent for next generation compounds to treat neurodegenerative diseases.

Alterity Therapeutics stock more than doubles on massive volume after new patent announcement

MELBOURNE, Australia, Nov. 16, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product...

Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases

MELBOURNE, Australia and SAN FRANCISCO, Oct. 26, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States. BioMUSE is a...

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

Alterity Therapeutics Ltd. (NASDAQ: ATHE) stock more than doubled on Tuesday after the company announced new data for its lead drug candidate ATH434.

What You Need to Know About Alterity Therapeutics’ Tuesday Move

Shares of Alterity Therapeutics Ltd. ATHE, -7.53% nearly tripled (up 173%) toward a 3-year high on heavy volume in premarket trading Tuesday, after the therapeutic drugs developer said it will present positive data for its lead drug candidate ATH434 for the treatment of multiple system atrophy (MSA), a Parkinsonian disorder.

Alterity's stock nearly triples on heavy volume after update on study of treatment for MSA, Parkinson's

The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.

Alterity Therapeutics Shares Surge As Company Says Animal Testing Data Positive For MSA Drug

Highlights: FDA provides guidance for ATH434 development pathway Company compliant with minimum NASDAQ price End of period cash balance of $9.2M bolstered by $1.5M following issue of shares on 2 July MELBOURNE, Australia and SAN FRANCISCO, July 30, 2020 /PRNewswire/ -- Alterity.

Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report

Alterity Therapeutics shares are trading higher on Tuesday after the company announced it received a development pathway from its meeting with the FDA for ATH434.

Why Alterity Therapeutics Stock Is Trading Higher Today

Alterity Therapeutics Ltd. (NASDAQ: ATHE) says it has received an update from the U.S.

News for Alterity Therapeutics Ltd - ADR Stock (ATHE)